Drug-metabolizing Enzyme, Transporter, and Nuclear Receptor Genetically Modified Mouse Models

Overview

Journal Drug Metab Rev

Publisher Informa Healthcare

Specialty Pharmacology

Date 2010 Sep 22

PMID 20854191

Citations 16

Authors

Xi-Ling Jiang

Frank J Gonzalez

Ai-Ming Yu

Affiliations

Soon will be listed here.

Abstract

Determining the in vivo significance of a specific enzyme, transporter, or xenobiotic receptor in drug metabolism and pharmacokinetics may be hampered by gene multiplicity and complexity, levels of expression, and interaction between various components involved. The development of knockout (loss-of-function) and transgenic (gain-of-function) mouse models opens the door to the improved understanding of gene function in a whole-body system. There is also growing interest in the development of humanized mice to overcome species differences in drug metabolism and disposition. This review, therefore, aims to summarize and discuss some successful examples of drug-metabolizing enzyme, transporter, and nuclear-receptor genetically modified mouse models. These genetically modified mouse models have been proven as invaluable models for understanding in vivo function of drug-metabolizing enzymes, transporters, and xenobiotic receptors in drug metabolism and transport, as well as predicting potential drug-drug interaction and toxicity in humans. Nevertheless, concerns remain about interpretation of data obtained from such genetically modified mouse models, in which the expression of related genes is altered significantly.

Citing Articles

Efflux ABC transporters in drug disposition and their posttranscriptional gene regulation by microRNAs.

Wang Y, Tu M, Yu A Front Pharmacol. 2024; 15:1423416.

PMID: 39114355 PMC: 11303158. DOI: 10.3389/fphar.2024.1423416.

Assessing cytochrome P450 function using genetically engineered mouse models.

Hannon S, Ding X Adv Pharmacol. 2022; 95:253-284.

PMID: 35953157 PMC: 10544722. DOI: 10.1016/bs.apha.2022.05.008.

Effects of total parenteral nutrition on drug metabolism gene expression in mice.

Ferrucci-Da Silva C, Zhan L, Shen J, Kong B, Campbell M, Memon N Acta Pharm Sin B. 2020; 10(1):153-158.

PMID: 31993312 PMC: 6976970. DOI: 10.1016/j.apsb.2019.10.012.

Membrane transporter data to support kinetically-informed chemical risk assessment using non-animal methods: Scientific and regulatory perspectives.

Clerbaux L, Paini A, Lumen A, Osman-Ponchet H, Worth A, Fardel O Environ Int. 2019; 126:659-671.

PMID: 30856453 PMC: 6441651. DOI: 10.1016/j.envint.2019.03.003.

The safety evaluation of food flavouring substances: the role of metabolic studies.

Smith R, Cohen S, Fukushima S, Gooderham N, Hecht S, Guengerich F Toxicol Res (Camb). 2018; 7(4):618-646.

PMID: 30090611 PMC: 6062396. DOI: 10.1039/c7tx00254h.

References

Fang C, Behr M, Xie F, Lu S, Doret M, Luo H . Mechanism of chloroform-induced renal toxicity: non-involvement of hepatic cytochrome P450-dependent metabolism. Toxicol Appl Pharmacol. 2007; 227(1):48-55. PMC: 2274901. DOI: 10.1016/j.taap.2007.10.014. View

Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, Inui K . Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol. 2009; 75(6):1280-6. DOI: 10.1124/mol.109.056242. View

Conklin D, Haberzettl P, Prough R, Bhatnagar A . Glutathione-S-transferase P protects against endothelial dysfunction induced by exposure to tobacco smoke. Am J Physiol Heart Circ Physiol. 2009; 296(5):H1586-97. PMC: 2685347. DOI: 10.1152/ajpheart.00867.2008. View

Xia C, Milton M, Gan L . Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr Drug Metab. 2007; 8(4):341-63. DOI: 10.2174/138920007780655423. View

Nguyen N, Bonzo J, Chen S, Chouinard S, Kelner M, Hardiman G . Disruption of the ugt1 locus in mice resembles human Crigler-Najjar type I disease. J Biol Chem. 2008; 283(12):7901-11. DOI: 10.1074/jbc.M709244200. View

Manautou J, de Waart D, Kunne C, Zelcer N, Goedken M, Borst P . Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology. 2005; 42(5):1091-8. DOI: 10.1002/hep.20898. View

Jonker J, Wagenaar E, Van Eijl S, Schinkel A . Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol. 2003; 23(21):7902-8. PMC: 207626. DOI: 10.1128/MCB.23.21.7902-7908.2003. View

Bonzo J, Belanger A, Tukey R . The role of chrysin and the ah receptor in induction of the human UGT1A1 gene in vitro and in transgenic UGT1 mice. Hepatology. 2007; 45(2):349-60. DOI: 10.1002/hep.21481. View

Zhou S, Morris J, Barnes Y, Lan L, Schuetz J, Sorrentino B . Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci U S A. 2002; 99(19):12339-44. PMC: 129446. DOI: 10.1073/pnas.192276999. View

10.

Gu J, Weng Y, Zhang Q, Cui H, Behr M, Wu L . Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem. 2003; 278(28):25895-901. DOI: 10.1074/jbc.M303125200. View

11.

Dai G, Chou N, He L, Gyamfi M, Mendy A, Slitt A . Retinoid X receptor alpha Regulates the expression of glutathione s-transferase genes and modulates acetaminophen-glutathione conjugation in mouse liver. Mol Pharmacol. 2005; 68(6):1590-6. DOI: 10.1124/mol.105.013680. View

12.

Mutch D, Crespy V, Clough J, Henderson C, Lariani S, Mansourian R . Hepatic cytochrome P-450 reductase-null mice show reduced transcriptional response to quercetin and reveal physiological homeostasis between jejunum and liver. Am J Physiol Gastrointest Liver Physiol. 2006; 291(1):G63-72. DOI: 10.1152/ajpgi.00565.2005. View

13.

Wu Y, Zhang X, Bardag-Gorce F, Robel R, Aguilo J, Chen L . Retinoid X receptor alpha regulates glutathione homeostasis and xenobiotic detoxification processes in mouse liver. Mol Pharmacol. 2004; 65(3):550-7. DOI: 10.1124/mol.65.3.550. View

14.

van Herwaarden A, Jonker J, Wagenaar E, Brinkhuis R, Schellens J, Beijnen J . The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res. 2003; 63(19):6447-52. View

15.

Gonzalez F, Kimura S . Study of P450 function using gene knockout and transgenic mice. Arch Biochem Biophys. 2002; 409(1):153-8. DOI: 10.1016/s0003-9861(02)00364-8. View

16.

Yu A, Granvil C, Haining R, Krausz K, Corchero J, Kupfer A . The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine. J Pharmacol Exp Ther. 2003; 304(2):539-46. DOI: 10.1124/jpet.102.043786. View

17.

Wei P, Zhang J, Liang S, Moore D . The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature. 2000; 407(6806):920-3. DOI: 10.1038/35038112. View

18.

Manis J . Knock out, knock in, knock down--genetically manipulated mice and the Nobel Prize. N Engl J Med. 2007; 357(24):2426-9. DOI: 10.1056/NEJMp0707712. View

19.

Gu J, Chen C, Wei Y, Fang C, Xie F, Kannan K . A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition. J Pharmacol Exp Ther. 2007; 321(1):9-17. DOI: 10.1124/jpet.106.118240. View

20.

Rao A, Haywood J, Craddock A, Belinsky M, Kruh G, Dawson P . The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis. Proc Natl Acad Sci U S A. 2008; 105(10):3891-6. PMC: 2268840. DOI: 10.1073/pnas.0712328105. View